@SashaGusevPosts @Mo_Safavi From an earlier thread, you shared some external validation data about the BOADICEA, which seemed pretty well-calibrated. That in itself already guarantees non-harmful decision-making. It seems there are some examples reporting
Predicting contralateral breast cancer and the corresponding clinical decision making may be a bit easier especially when additional genetic information beyond BRCA1/2 such as polygenic risk score and CHEK2 c.1100delC are also included in the model. http
PredictCBC-2.0: a contralateral #breastcancer risk prediction model developed and validated in ~ 200,000 patients: https://t.co/nrpzh9PVSp https://t.co/vFUdurPWP2
PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients #HelsinkiHealth #tutkimus #tiede https://t.co/MrGgXgQDvp